Early-Phase Oncology Research in the Community Setting

What “early phase” can include

Early-phase oncology may refer to a first-in-human study, a new combination of known and investigational agents, a dose-escalation cohort, a food-effect or drug-interaction question, or an expansion cohort in a selected disease or biomarker group. Protocols may be labeled Phase 1, Phase 1b, Phase 1/2, or another development description.

Common objectives include identifying a tolerable dose or schedule, characterizing adverse effects, measuring drug concentrations over time, confirming biological target effects, and observing preliminary antitumor activity. These studies involve uncertainty. Early evidence may be limited, and participation does not guarantee benefit.

Why community access matters

Travel to a distant center can create barriers involving time, transportation, lodging, work, caregiving, and repeated visits. Community research can bring selected trials closer to where many patients receive care. The National Cancer Institute's community research programs demonstrate the broader value of conducting cancer research in community settings and reaching populations beyond major academic centers.

Proximity can support participation, but it should never substitute for capability. A local site must still meet the same protocol, ethical, safety, documentation, and data expectations that apply to the study.

Infrastructure must match the protocol

Early-phase requirements vary, but a capable site may need:

• •Investigators experienced in oncology research and available for real-time decisions
• •Research nursing and coordination for complex visits
• •Pharmacy controls for storage, preparation, accountability, dose changes, and blinding when applicable
• •Laboratory capability for timed pharmacokinetic and biomarker samples
• •Access to imaging, electrocardiography, biopsies, and other protocol procedures
• •Extended observation space and clearly defined emergency response
• •Electronic systems, source documentation, and rapid data entry
• •After-hours clinical and safety escalation
• •Backup staff and contingency plans for equipment, couriers, and scheduling disruptions

The site should test the visit sequence in advance. A protocol with 12 timed blood draws is not simply a calendar with 12 appointments; it is a coordinated system involving venous access, accurate timestamps, processing, storage, documentation, staff breaks, treatment timing, and participant comfort.

Safety depends on fast, qualified decisions

In dose escalation, information from one participant or site may affect decisions for others. Symptoms and laboratory abnormalities must reach qualified investigators promptly. Dose-limiting toxicity windows, serious adverse event reporting, and sponsor notifications may have strict requirements.

A community site conducting this work needs reliable investigator coverage and access to appropriate emergency services. Staff should know which problems can be managed through protocol guidance, which require immediate investigator assessment, and how outside emergency clinicians receive relevant study information.

Referral partnerships support continuity

The treating oncologist contributes knowledge of the patient's disease history, prior response, toxicity, and goals. The research investigator contributes protocol-specific assessment and responsibility for study conduct. Clear communication between them can support timing, screening, management of shared issues, and the transition after study treatment.

Patients should know which team manages investigational treatment, routine cancer needs, chronic conditions, and urgent concerns. A research site should not imply that referral requires abandoning the established oncology relationship.

Patient experience remains central

Early-phase schedules can be demanding. Consent should explain the purpose, uncertainty, alternatives, possible risks, biopsies or extra samples, visit intensity, hospitalization or observation requirements when applicable, and what happens if treatment stops. Practical planning should address language, transportation, caregiver support, work, food, and long visit days.

The desire for an investigational option can make patients vulnerable to overly optimistic messages. Communication should remain precise: a scientifically relevant trial is not a promise of eligibility, treatment access, safety, tumor response, or benefit.

What Sponsors should evaluate

For a community early-phase site, Sponsors and CROs should examine:

• •Investigator experience, access, and competing commitments
• •Evidence supporting the eligible patient population and referral reach
• •Pharmacy, laboratory, equipment, and procedure capability
• •First-cycle staffing and capacity for extended visits
• •Safety escalation, backup coverage, and emergency pathways
• •Sample, data, and query performance
• •Quality management and audit readiness
• •Communication with referring clinicians and participants

The qualification decision should match the cohort and protocol, not a generic site category.

Our FCTG approach

At FCTG, our research-only oncology model is designed to support selected early-phase work in the South Florida community. Our physician investigators assess the scientific and clinical fit, while our operational team evaluates the patient population, pharmacy and laboratory readiness, time-sensitive procedures, safety oversight, staff capacity, and referral continuity. We accept a protocol only when that fit can be documented and supported responsibly.